News | Clinical Trials | December 06, 2019

Acupuncture Reduces Radiation-induced Dry Mouth for Cancer Patients

Patients who had acupuncture during radiation reported less dry mouth symptoms up to 12 months after treatment

After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center

Image by Rudolf Langer from Pixabay 

December 6, 2019 — After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center.

The trial results, published in JAMA Network Open, is the first randomized, placebo-controlled, Phase III trial to evaluate the use of acupuncture during radiation therapy to reduce the incidence and severity of radiation-induced xerostomia, or dry mouth. Acupuncture treatment has very few side effects and is relatively low cost compared to standard treatments such as medication and saliva substitutes. These results support a 2011 study that found symptoms improved up to six months after radiation treatment with concurrent acupuncture sessions.

"Dry mouth is a serious concern for head and neck cancer patients undergoing radiation therapy. The condition can affect up to 80 percent of patients by the end of radiation treatment," said the study's principal investigator, Lorenzo Cohen, Ph.D., professor of Palliative, Rehabilitation, and Integrative Medicine and director of the Integrative Medicine Program. "The symptoms severely impact quality of life and oral health, and current treatments have limited benefits."

True acupuncture (TA) had significantly lower xerostomia scores than standard care control (SCC) and marginally lower than the sham acupuncture (SA), with no differences between SA and SCC. One year after the end of radiation therapy, the incidence of clinically significant xerostomia was 35 percent in the TA group, 48 percent in the SA group and 55 percent in the SCC group.

The study included 339 head and neck cancer patients undergoing radiation treatment at MD Anderson and Fudan University Cancer Center in Shanghai between Dec. 16, 2011 and July 7, 2015. The patients were divided into three groups. One group received true acupuncture, another group received sham acupuncture and the third group, the SCC group, received radiation and oral health education but no acupuncture. None had received acupuncture prior to participating in the study.

Patients assigned to either TA or SA received acupuncture three days a week on the same day as their radiation treatment, which lasted six to seven weeks. The sham procedure involved a real needle at a point not indicated for xerostomia, real needles at sham points and placebo needles at sham points.

Results were based on data derived from a self-report questionnaire. Patients completed the Xerostomia Questionnaire (XQ), an eight-item survey assessing symptoms of the condition. XQ scores under 30 corresponded to mild or no symptoms of xerostomia. The data was collected at baseline, at the end of radiotherapy, and three, six and 12 months after radiation treatment.

TA resulted in significantly fewer and less severe dry mouth symptoms one year after treatment. The xerostomia score in the TA group was 26.6 vs 31.3 in the SA group and 34.8 in the SCC group.

The Acupuncture Expectancy Scale (AES) was used to measure the relationship between expectations related to acupuncture and clinical response. Patients completed the AES at baseline, after four acupuncture sessions and at the end of acupuncture treatment. There were no group differences or differences between sites.

"The evidence is to a point where patients should incorporate acupuncture alongside radiation treatment as a way to prevent the severity of dry mouth symptoms," said Cohen. "I think with this study we can add acupuncture to the list for the prevention and treatment of xerostomia, and the guidelines for the use of acupuncture in the oncology setting should be revised to include this important chronic condition."

A secondary analysis showed a significant difference between sites in response to placebo. The Chinese patients had little to no placebo response to sham acupuncture whereas the MD Anderson patients had a large placebo response, showing both forms of acupuncture worked. More studies are needed to understand these site differences, but it has been suggested that it could be due to the environment in which the acupuncture is delivered, cultural influences or the relationship between patient and practitioner.

Future studies will focus on ensuring acupuncture delivery is well controlled and will evaluate inconsistencies in response to sham acupuncture. Additional studies are needed to confirm the trial results and better understand the neurological mechanisms of acupuncture.

For more information: https://www.mdanderson.org/

Related Content

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 09, 2021
April 9, 2021 — According to an open-acc...
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc
Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Lung Imaging | March 29, 2021
March 29, 2021 — According to ARRS' 
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of